Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- (OC-6-13)-dichloro[7,12-diethenyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoato(4-)-?N21,?N22,?N23,?N24]-stannate(2-), dihydrogen
- Correlated keywords
- 744952-85-0 99022-?74-?9 inhibitors inhibits inhibitions oxidative injury injuries heme oxygenase HO synthetics analogs selective selectively HO-1 HO-2 endothelial nitric oxide NO synthase soluble guanylyl cyclases hyperbilirubinemia neonates plasma tissues kidneys livers spleens cells animals eNOS NSCs 267099 NSC267099 NSC-267099 SnPP IX SnPP-IX
- Product Overview:
Heme oxygenase (HO) converts protoheme to biliverdin, which in turn is enzymatically metabolized to bilirubin (Item No. 17161). While HO-2 is constitutively expressed, HO-1 can be induced by its heme substrate as well as by heavy metals, oxidizing agents, and other environmental stresses.{19790,4647,17438} Tin protoporphyrin IX (SnPPIX) is a synthetic heme analog that selectively inhibits HO-1 (Ki = 11 nM) over HO-2 (IC50 = 7.5 µM).{26672,26673} It also weakly inhibits endothelial nitric oxide synthase and soluble guanylyl cyclase (IC50s = 35 and 30 nM, respectively).{26673} SnPPIX prevents hyperbilirubinemia in neonates by blocking HO-1 activity that increases postnatally.{26672} It is rapidly cleared from plasma and persists in certain tissues, including kidney, liver, and spleen.{26671} SnPPIX is commonly used as a tool to study the role of HO-1 activity in cells and in animals.{26675,26674}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.